Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0OHPNA
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
huAb18v9-CZ
|
|||||
| Synonyms |
huAb18v9 CZ; huAb18v9CZ
Click to Show/Hide
|
|||||
| Organization |
AbbVie, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Breast ductal carcinoma [ICD11:2C61]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2.4
|
|||||
| Structure |
|
|||||
| Antibody Name |
huAb18v9
|
Antibody Info | ||||
| Antigen Name |
CD276 antigen (CD276)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
huAb18v9-CZ linker
|
|||||
| Combination Type |
AbbVie's CZ
|
|||||
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
| Standard Type | Value | Units | Cell Line | Disease Model |
|---|---|---|---|---|
| Tumor Growth Inhibition value (TGI) |
83
|
%
|
NCI-H146 cells
|
Small cell carcinoma
|
Revealed Based on the Cell Line Data
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | 83.00% | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
In vivo xenograft model of small cell lung cancer (using NCI-H146 cells). Single dose treatment of the tumor bearing mice resulted in tumor growthinhibition and tumor growth delay. Mice were administered 6 mg/kg of the ADC intraperitoneally IP/QDx1.
|
||||
| In Vivo Model | NCI-H146 CDX model | ||||
| In Vitro Model | Small cell carcinoma | NCI-H146 cells | CVCL_1473 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.90 nM | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
Humanized chAb18 variants were conjugated to the CZ synthon and tested for cytotoxicity in HCC38 cell line.
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC38 cells | CVCL_1267 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | 0.90 nM | Positive CD276 expression (CD276 +++/++) | ||
| Method Description |
The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the HCC38 cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
|
||||
| In Vitro Model | Breast ductal carcinoma | HCC38 cells | CVCL_1267 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.